[HTML][HTML] Targeting KRAS in Cancer: Promising Therapeutic Strategies

LM Mustachio, A Chelariu-Raicu, L Szekvolgyi… - Cancers, 2021 - mdpi.com
Simple Summary Since the Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated
in about 25% of all human cancers and is at the center of pathways involved in …

Immunotherapy in endometrial cancer

H Mahdi, A Chelariu-Raicu… - International Journal of …, 2023 - ijgc.bmj.com
The Cancer Genome Atlas (TCGA) endometrial cancer data expanded our knowledge about
the role of different immunotherapeutic approaches based on molecular subtypes. Immune …

Integrating antibody drug conjugates in the management of gynecologic cancers

A Chelariu-Raicu, S Mahner, KN Moore… - International Journal of …, 2023 - ijgc.bmj.com
The clinical development of antibody drug conjugates (ADCs) in ovarian cancer began in
2008 with farletuzumab, a humanized monoclonal antibody, and vintafolide, an antigen drug …

Phase Ib dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple-negative breast, and ovarian cancer

SN Westin, M Labrie, JK Litton, A Blucher, Y Fang… - Clinical Cancer …, 2021 - AACR
Purpose: On the basis of strong preclinical rationale, we sought to confirm recommended
phase II dose (RP2D) for olaparib, a PARP inhibitor, combined with the AKT inhibitor …

[HTML][HTML] Development and validation of a novel 11-gene prognostic model for serous ovarian carcinomas based on lipid metabolism expression profile

M Zheng, H Mullikin, A Hester, B Czogalla… - International journal of …, 2020 - mdpi.com
(1) Background: Biomarkers might play a significant role in predicting the clinical outcomes
of patients with ovarian cancer. By analyzing lipid metabolism genes, future perspectives …

[HTML][HTML] COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective

M Forster, R Wuerstlein, A Koenig, N Amann, S Beyer… - The Breast, 2021 - Elsevier
Introduction The side effects of systemic cancer therapy and the lack of clinical data on
safety and efficacy of COVID-19 vaccination in cancer patients cause uncertainty among the …

Prostaglandin E2 receptor 3 promotes M1 macrophages polarization in unexplained recurrent pregnancy loss

Y Ye, L Peng, A Chelariu-Raicu, C Kuhn… - Biology of …, 2022 - academic.oup.com
Unexplained recurrent pregnancy loss (uRPL) is associated with macrophage polarization,
which can be modulated by prostaglandin E2 (PGE2). Our previous study demonstrated that …

[HTML][HTML] The cell surface heparan sulfate proteoglycan syndecan-3 promotes ovarian cancer pathogenesis

L Hillemeyer, NA Espinoza-Sanchez, B Greve… - International Journal of …, 2022 - mdpi.com
Syndecans are transmembrane heparan sulfate proteoglycans that integrate signaling at the
cell surface. By interacting with cytokines, signaling receptors, proteases, and extracellular …

[HTML][HTML] Identification of a novel tumor microenvironment prognostic signature for advanced-stage serous ovarian cancer

M Zheng, J Long, A Chelariu-Raicu, H Mullikin… - Cancers, 2021 - mdpi.com
Simple Summary The expression of tumor microenvironment-related genes is known to be
correlated with ovarian cancer patients' prognosis. Immunotherapeutic targets are in part …

Updates of Placental Macrophages: origins, molecular markers, functions, and related diseases

H Yang, A Chelariu-Raicu, D Makri, C Ori… - Journal of Reproductive …, 2023 - Elsevier
Placental macrophages are highly heterogeneous cells with differential phenotypes and
functions defined by differential origins and modulated by the changing placental …